Aura Biosciences Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma

Source: Aura Biosciences

Aura Biosciences announced that Julie Feder has joined the company’s leadership team as Chief Financial Officer, and Kylie Reynolds has been named Vice President of Finance. The moves come as the company finalizes its phase 1/2 clinical trial and prepares to initiate late stage clinical development for its flagship drug in choroidal melanoma next year.

“We’re excited to welcome Julie and Kylie to our team at this important moment for our company,” Elisabet de los Pinos, PhD, founder and CEO of Aura, said in a company news release. “Their combined four-plus decades of experience in financial management will be an asset in our accelerated progress towards developing a groundbreaking new treatment for patients with choroidal melanoma.”

Ms. Feder joins Aura from Verastem, where she served as Chief Financial Officer. At Verastem, Ms. Feder was responsible for developing the company’s strategic financial plan and overseeing a rapid growth in financing and staff size. Prior to joining Verastem, Ms. Feder spent 6 years at the Clinton Health Access Initiative (CHAI) as Chief Financial Officer. At CHAI, Ms. Feder was responsible for managing a global team across multiple departments. She also developed the global finance strategy and internal audit, treasury, and global payroll functions. Ms. Feder holds a Bachelor of Science in Accounting from Yeshiva University’s Sy Syms School of Business.

Ms. Reynolds comes to Aura from Forma Therapeutics, where she served as Senior Director and Controller for the company since 2015. In that role, Ms. Reynolds was responsible for assessing systems, people and processes to prepare the company for financial transformation. Ms. Reynolds holds an M.S. in Banking and Financial Management from Boston University and is a Certified Public Accountant.


Related Content